Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | APROMISS: catequentinib hydrochloride in alveolar soft part sarcoma

Margaret von Mehren • 31 May 2026
ASCO 2026
Sarcoma Catequentinib
APROMISS

Margaret von Mehren, MD, Fox Chase Cancer Center, Philadelphia, PA, presents results from the APROMISS trial (NCT03016819) of catequentinib hydrochloride, an oral multitargeted receptor tyrosine kinase inhibitor (TKI), in patients with advanced alveolar soft part sarcoma (ASPS). Despite the objective response rate falling marginally below the predefined threshold, results demonstrated prolonged disease control, durable responses, and favorable progression-free and overall survival outcomes, alongside a manageable safety profile. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Margaret von Mehren

VEBrant: vebreltinib efficacy and safety in advanced clear cell sarcoma
2:18
VEBrant: vebreltinib efficacy and safety in advanced clear cell sarcoma
Margaret von Mehren • 31 May 2026
Where does immunotherapy fit in the treatment landscape of sarcoma?
3:59
Where does immunotherapy fit in the treatment landscape of sarcoma?
Margaret von Mehren • 26 May 2021
Optimizing treatment approaches for the management of GIST
2:29
Optimizing treatment approaches for the management of GIST
Margaret von Mehren • 26 May 2021
Ribociclib plus everolimus in advanced dedifferentiated liposarcoma
3:25
Ribociclib plus everolimus in advanced dedifferentiated liposarcoma
Margaret von Mehren • 26 May 2021

Related Videos

VEBrant: vebreltinib efficacy and safety in advanced clear cell sarcoma
2:18
VEBrant: vebreltinib efficacy and safety in advanced clear cell sarcoma
Margaret von Mehren • 31 May 2026
The importance of center volume in improving outcomes for sarcoma
1:21
The importance of center volume in improving outcomes for sarcoma
Marco Fiore • 16 Oct 2025
Surgical planning in soft tissue sarcomas
1:49
Surgical planning in soft tissue sarcomas
Marco Fiore • 16 Oct 2025
IDH1-targeted therapy potential in advanced chondrosarcoma
1:09
IDH1-targeted therapy potential in advanced chondrosarcoma
Robin Jones • 19 Oct 2025
The content of VJOncology is intended for healthcare professionals